Mitsubishi UFJ Asset Management Co. Ltd. Has $264.99 Million Stock Holdings in Pfizer Inc. $PFE

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Pfizer Inc. (NYSE:PFE) by 7.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,931,822 shares of the biopharmaceutical company’s stock after purchasing an additional 775,358 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.19% of Pfizer worth $264,987,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth $27,000. Curio Wealth LLC increased its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. acquired a new position in Pfizer during the second quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer in the first quarter valued at approximately $35,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $24.45 on Friday. The firm has a market cap of $138.99 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock’s fifty day moving average price is $24.74 and its two-hundred day moving average price is $24.35. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PFE. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. UBS Group restated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.